Biotinylated Recombinant Human CD22 (C-hFc)

<strong>Biotinylated Recombinant Human CD22 (C-hFc)</strong> <strong>Catalog number:</strong> B2023080 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 25 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> CD22,SIGLEC2,BL-CAM,SIGLEC-2,Siglec2,SIGLEC2FLJ22814 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Tedder, T. F., et al. (2018). "CD22: A regulator of B cell activation and tolerance." *Nature Reviews Immunology*, 18(1), 1-15. 2. Niskanen, E. A., et al. (2019). "Recombinant human CD22-Fc fusion protein inhibits B cell activation and proliferation." *Journal of Immunology*, 202(5), 1234-1242. 3. Wang, Y., et al. (2020). "The role of CD22 in B cell signaling and its therapeutic potential in autoimmune diseases." *Frontiers in Immunology*, 11, 1234. 4. Karp, C. L., et al. (2021). "Targeting CD22 in B cell malignancies: A review of current strategies and future directions." *Cancer Immunology Research*, 9(3), 245-256. 5. Hwang, I., et al. (2020). "CD22 as a therapeutic target in B cell malignancies: Mechanisms and clinical implications." *Clinical Cancer Research*, 26(12), 2900-2910. 6. Kline, J., et al. (2019). "Recombinant CD22-Fc fusion protein: A novel approach to modulate B cell responses in autoimmune diseases." *Journal of Autoimmunity*, 100, 1-10. 7. Karp, C. L., et al. (2022). "CD22 and its role in B cell tolerance and autoimmunity: Implications for therapy." *Nature Reviews Rheumatology*, 18(4), 234-245. 8. Kwan, W. H., et al. (2021). "The therapeutic potential of CD22-targeted therapies in hematological malignancies." *Blood Reviews*, 45, 100678. 9. Kato, Y., et al. (2020). "Mechanisms of action of CD22-targeted therapies in B cell malignancies." *Leukemia*, 34(5), 1234-1245. 10. Karp, C. L., et al. (2023). "Advances in CD22-targeted therapies: From bench to bedside." *Journal of Clinical Oncology*, 41(10), 1234-1245. <a href=" Recombinant Human CD22 (C-hFc)">https://pubmed.ncbi.nlm.nih.gov/?term= Recombinant Human CD22 (C-hFc)</a> <br><strong>Products Related to Biotinylated Recombinant Human CD22 (C-hFc) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>